For people living with primary progressive aphasia (PPA), a rare, early-onset neurodegenerative dementia that predominantly ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Study results suggest that “telemedicine represents a unique opportunity to reduce time and travel burdens for patients with cancer considering clinical trials,” according to researchers.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

“Our CB-SCs can target different compartments of the immune system, educating and correcting their dysfunctions at a fundamental level,” says Dr. Zhao. “This therapy has the potential to revolutionize ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

When you have both ulcerative colitis (UC) and diabetes, it’s a balancing act. The two diseases can overlap and interact in frustrating ways, and sometimes treating one condition worsens ...

Troy Ita’s life was turned upside down by diabetes. Thankfully, he doesn’t have to compromise lifestyle or family time with ...